Rising life expectancy worldwide is accompanied by an increasing medical need for effective treatments for cardiovascular diseases such as heart attack, stroke and heart failure (HF). Now, new innovative drugs are available to combat cardiovascular and kidney diseases are available or in the pipeline.
The European Commission has granted marketing authorization for finerenone under the brand name Kerendia® in the European Union (EU). According to a large clinical trial, the non-steroidal selective mineralocorticoid receptor antagonist (MRA) has been shown to protect the heart and kidneys of patients with chronic kidney disease associated with type 2 diabetes by blocking mineralocorticoid receptor (MR) overactivation.
The active ingredient vericiguat (Verquvo®) is used to treat adults with chronic heart failure and reduced ejection fraction who have recently received intravenous treatment due to a decompensation event (sudden worsening of heart failure). The drug has been shown to reduce the risk of cardiovascular death and hospitalizations due to heart failure and is approved in the U.S., Europe and Japan, among other countries, for the treatment of heart failure.
let
Factor XIa inhibitors in the pipeline
FXIa inhibitors may become a treatment option for patients who have not had the opportunity to be treated with an anticoagulant. These are, for example, patients with atrial fibrillation and at the same time a high risk of bleeding. Several promising compounds in this class, such as asundexian, osocimab and fesomersen, are in the pipeline.
Source: Annual Bayer Pharma Media Day 2022
CARDIOVASC 2022; 21(2): 38
